Citigroup Forecasts Strong Price Appreciation for Larimar Therapeutics (NASDAQ:LRMR) Stock

Larimar Therapeutics (NASDAQ:LRMR) had its price objective boosted by Citigroup from $12.00 to $14.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price objective points to a potential upside of 153.62% from the company’s previous close.

A number of other brokerages have also weighed in on LRMR. Leerink Partners upgraded Larimar Therapeutics to a “strong-buy” rating in a research report on Monday, January 5th. Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Larimar Therapeutics in a report on Wednesday. Lifesci Capital upgraded shares of Larimar Therapeutics to a “strong-buy” rating in a report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Larimar Therapeutics currently has an average rating of “Buy” and a consensus target price of $16.14.

Larimar Therapeutics Stock Performance

NASDAQ LRMR opened at $5.52 on Wednesday. The firm’s fifty day moving average price is $3.53 and its two-hundred day moving average price is $3.79. The stock has a market cap of $456.95 million, a PE ratio of -2.86 and a beta of 1.00. Larimar Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $6.42.

Institutional Trading of Larimar Therapeutics

A number of institutional investors have recently bought and sold shares of the company. AIGH Capital Management LLC bought a new stake in shares of Larimar Therapeutics during the 3rd quarter valued at about $3,230,000. Ethic Inc. acquired a new position in Larimar Therapeutics in the second quarter valued at approximately $187,000. XTX Topco Ltd acquired a new position in Larimar Therapeutics in the second quarter valued at approximately $484,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Larimar Therapeutics by 70.6% during the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 307,198 shares of the company’s stock worth $888,000 after buying an additional 127,171 shares in the last quarter. Finally, CWM LLC grew its position in shares of Larimar Therapeutics by 205.0% during the 2nd quarter. CWM LLC now owns 32,652 shares of the company’s stock worth $94,000 after buying an additional 21,948 shares during the period. Institutional investors own 91.92% of the company’s stock.

More Larimar Therapeutics News

Here are the key news stories impacting Larimar Therapeutics this week:

• Positive Sentiment: Lifesci Capital upgraded LRMR to a “Strong-Buy” and published Q4 2025 and FY2025 EPS estimates (Q4: ($0.41); FY2025: ($1.70)), signaling analyst confidence in the company’s outlook and supporting demand for the shares. MarketBeat Lifesci Note
• Positive Sentiment: Citigroup raised its price target to $14 (buy), and Wedbush reaffirmed an outperform rating with an $11 target — both represent substantial upside vs. the current level and underpin bullish analyst sentiment. Benzinga
• Positive Sentiment: Unusually large call-option activity occurred (several thousand calls bought), suggesting short-term bullish positioning by traders and contributing to intraday spikes before the equity raise announcement. (No direct article link provided)
• Positive Sentiment: Coverage and commentary explaining the intraday rally were published (coverage noted a ~22% intraday rise before the selloff), which can attract momentum buyers and increased attention. AAII Article
• Neutral Sentiment: The company initially announced a proposed $75M underwritten offering (preliminary press release) — this first filing signaled capital raise intent before the deal was upsized. GlobeNewswire – Proposed Offering
• Negative Sentiment: Larimar priced an upsized underwritten public offering of 20,000,000 shares at $5.00 per share (gross proceeds ~$100M) and granted a 30-day option for an additional 3,000,000 shares — direct dilution and increased share supply are the main catalysts pressuring the stock. GlobeNewswire – Priced Offering

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.